Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

Abstract The efficacy and safety of sitagliptin as monotherapy were evaluated in Chinese, Indian, and Korean patients with type 2 diabetes inadequately controlled by diet and exercise. In a randomized, placebo-controlled, double-blind, 18-week trial, 530 patients with HbA1c ≥7.5% and ≤11.0% (mean baseline 8.7%) received sitagliptin 100 mg once daily or placebo. Compared with placebo, sitagliptin significantly ( p < 0.001) reduced mean HbA1c (−1.0%), fasting plasma glucose (−1.7 mmol/L), and 2-h postprandial glucose (−3.1 mmol/L), and a significantly (p < 0.001) greater proportion of sitagliptin-treated versus placebo-treated patients achieved HbA1c